Cell & Gene Therapy

A proprietary vector discovery platform called Therapeutic Vector Evolution sits at the centre of 4DMT 's approach to genetic medicine. Rather than relying on existing delivery vehicles, the clinical-stage biopharma company engineers customised, proprietary gene delivery vectors matched to specific tissue types and routes of administration, with the goal of addressing large-market diseases where conventional treatments fall short. Founded in 2015 and headquartered in Emeryville, California, 4DMT trades on NASDAQ under the ticker FDMT. 4DMT's integrated product engine spans design, development and manufacturing, enabling the company to build a diverse clinical pipeline. Current therapeutic focus spans retinal diseases and pulmonary diseases, two areas with significant unmet need in which precision gene delivery to targeted tissue is critical. The company positions its work as striving for potential curative outcomes rather than symptomatic management, reflecting its stated ambition to unlock the full potential of genetic medicine. As a clinical-stage organisation, 4DMT combines platform innovation with pipeline execution, maintaining a scientific advisory structure that includes a dedicated Retina Advisory Board alongside broader scientific and corporate advisory boards. The company also supports internal diversity through its 4Diversity programme, which shapes workforce culture and recruitment practices. Further information is available at 4dmoleculartherapeutics.com.

ABL specialises in the development and manufacture of advanced biological therapeutics, with a particular focus on gene therapies, vaccines, oncolytics and immunotherapies . Working exclusively with client programmes rather than proprietary pipelines, the company positions itself as a dedicated development partner for organisations tackling some of the most complex disease areas in modern medicine. The company's manufacturing capabilities span virus manufacturing and process development, aseptic fill finish, and cell and virus banking. These services are supported by biologics and quality control testing, giving clients access to an integrated development pathway under a single provider. ABL also supplies ELISA kits as commercial products, reflecting a broader engagement with laboratory and analytical workflows. Government partnering is listed as a distinct service category, indicating that ABL works with public-sector and defence-adjacent clients in addition to commercial biotechnology and pharmaceutical sponsors. This positions the company within the wider landscape of biodefence and public health preparedness, alongside conventional clinical-stage biologics work. The organisation operates under the ABL, Inc. legal identity and maintains multiple locations, supporting projects across process development, manufacturing scale-up, and aseptic production. Its integrated service model is suited to sponsors requiring continuity across early development and late-stage manufacturing without transferring programmes between providers. Further information is available at ablinc.com.

Adaptimmune is built around a singular conviction: that engineered T-cells can be directed to fight cancer with precision and durability. The clinical-stage biopharmaceutical company focuses exclusively on cancer immunotherapy , developing cell therapies designed to arm a patient's own immune system against malignant disease. The company's pipeline has centred on next-generation T-cell receptor (TCR) therapies. Its named programmes include TECELRA, lete-cel, afami-cel, and uza-cel, all of which have been the subject of significant corporate activity. Adaptimmune announced the sale of these four cell therapies to US WorldMeds, a transaction that marks a strategic inflection point for the organisation and underscores the commercial value of its therapeutic assets. Trading on the Nasdaq under the ticker ADAPY, Adaptimmune has operated as a publicly listed entity, giving investors and industry partners visibility into its governance, pipeline progress and financial position. Its focus on T-cell receptor therapy places it within a specialised and competitive segment of oncology drug development, where target specificity and manufacturing scalability remain defining challenges. As a clinical-stage business, Adaptimmune's work sits at the intersection of translational science and commercial development, with programmes advancing from research through to patient-facing trials. The company publishes its pipeline status and scientific findings openly, providing industry professionals and research partners with access to its methodology and clinical data. Further information is available at adaptimmune.com.

Trusted by the cell and gene therapy sector since 2006, Akron Biotech supplies the ancillary materials that underpin advanced therapeutic manufacturing. Operating under the Akron Bio brand, the company occupies a specialised position in the biotech supply chain, providing the raw materials and contract services that research teams and commercial manufacturers depend on at every stage of development and scale-up. The product portfolio centres on three core categories: cytokines and growth factors , human plasma derived products, and media and media supplements. These materials are critical inputs for cell expansion, gene vector production, and the broader biomanufacturing workflows associated with advanced therapies. Alongside its catalogue offering, Akron Biotech runs dedicated manufacturing services covering proteins, media and buffers, and transfection and transduction reagents, giving clients a single source for both off-the-shelf supply and custom-manufactured components. Quality assurance is presented as a defining characteristic of the business. The company maintains regulatory support documentation and certificates for its materials, reflecting the compliance requirements of partners working in regulated therapeutic development environments. A knowledge centre comprising published posters, publications, and event resources further supports the scientific community using its products. Partnerships and collaborations form part of the company's stated commercial model, positioning Akron Biotech as an integrated supplier rather than a transactional vendor. Its leadership and newsroom functions suggest an active presence in the cell and gene therapy market rather than a passive catalogue role. Further information is available at akronbiotech.com.

Rooted in decades of albumin science first pioneered at Delta Biotechnology and later advanced under Novozymes Biopharma, Albumedix is a Nottingham-based biotechnology company that produces recombinant human serum albumin for pharmaceutical and bioprocessing applications. The company emerged as an independent entity following Novozymes' divestment of its biopharma operations, carrying forward a well-established manufacturing and regulatory heritage. Its flagship material, Recombumin, is expressed in Saccharomyces cerevisiae yeast and is entirely free of animal-derived and plasma-derived components. This origin gives manufacturers a consistent, traceable alternative to plasma-sourced albumin, addressing both supply-chain risk and evolving regulatory expectations around animal-free raw materials in biopharmaceutical production. Applications Across Biologics Manufacturing Albumin-based excipients supplied by Albumedix are used as stabilisers in vaccines, cell and gene therapy products, and protein biologics, where formulation integrity directly affects product shelf life and clinical performance. Beyond final-product formulation, Recombumin is also incorporated into cell culture media and bioprocessing workflows, supporting the growth of sensitive mammalian cell lines used in biologics development. The company operates under pharmaceutical-grade quality systems, with its materials referenced in regulatory dossiers for licensed medicines across multiple markets. Albumedix works with global pharmaceutical manufacturers, contract development and manufacturing organisations, and advanced therapy developers seeking compliant, well-characterised albumin raw materials. Further information is available at albumedix.com.

Europe's pioneer in integrated therapies for rare diseases and critical care, AOP Health (trading as AOP Orphan) brings together scientific rigour, clinical development and commercial delivery under one roof. The company operates at the intersection of rare disease medicine and intensive-care medicine, two areas where unmet patient need remains exceptionally high. The therapeutic focus spans cardiology and pulmonology, haemato-oncology, critical care, and advanced therapies. This breadth reflects a deliberate strategy to address conditions that are either underserved by mainstream pharmaceutical investment or require highly specialised clinical management. A patient story programme, including accounts of sepsis survival, illustrates the real-world impact the company seeks to communicate to partners, prescribers and policymakers alike. On the scientific side, AOP Health maintains an active clinical pipeline with new trials entering development, including a study of a novel treatment approach for blood cancers announced in June 2026. The company publishes its research findings and makes its innovation methodology available to industry audiences, reflecting an openness to scientific dialogue that is characteristic of organisations working in rare-disease areas subject to close regulatory scrutiny. AOP Health operates across multiple international locations and participates actively in the global congress calendar, including rare skin disease and haemato-oncology meetings. In June 2026, the company received a Gold award at the WKO Export Awards, recognising its performance as an Austrian exporter with international reach. This recognition underlines its standing as a commercially active, internationally operating pharmaceutical business, not merely a research-stage organisation. Further information is available at aop-health.com.

RSSL (Reading Scientific Services) operates across two major industry verticals, providing contract laboratory and scientific services to clients in life sciences and pharmaceuticals as well as food and consumer goods. Based in Reading, UK, the organisation positions itself as an outsourced testing and innovation partner covering everything from early research and discovery through to manufacturing, commercialisation, and regulatory compliance. Within the pharmaceutical and life science sector, RSSL offers testing across a broad range of molecule and product types, including biologics, cell and gene therapy, consumer healthcare, small molecule pharmaceuticals, vaccines, veterinary medicine, and specialised nutritional products. Services are organised by development phase, allowing clients to engage at preclinical stages, through clinical development, and into commercial-scale manufacturing. Capabilities span pharmacopoeial testing, ICH stability studies , contamination and impurity analysis, microbiology testing, and a rapid mycoplasma screening and detection service, which the company describes as fast, compliant, and sensitive. A priority response service is also available for time-critical projects. RSSL maintains an Innovation Hub and a dedicated services directory spanning techniques and methods to support product development across its client base. The food and consumer goods division extends these analytical capabilities into food and beverages, ingredients, consumer goods, food service, specialised nutrition, nutraceuticals, and dietary supplements. A recently announced dedicated nutritional testing service, supported by a £1.2 million investment, reflects continued capital commitment to expanding laboratory capacity in this area. Further information is available at rssl.com.

Antigen-specific immunotherapy is the clinical focus of Barinthus Biotherapeutics plc (formerly Vaccitech), a clinical-stage biopharmaceutical company dedicated to guiding T cells and antibodies to overcome autoimmunity and inflammatory disease. The company operates at the research and development frontier of immunology and inflammatory (I&I) indications, building on scientific foundations laid by academic institutions of international standing. Barinthus Bio emerged from the 2021 merger of Vaccitech, Plc, an Oxford University spinout, and Avidea Technologies, Inc., a spinout of the National Institutes of Health (NIH) and Johns Hopkins University. The combination united two complementary immunotherapeutics platforms and created a company with a broader base of T cell-directed therapeutic expertise than either predecessor held independently. The company's pipeline centres on autoimmunity, with its proprietary SNAP-TI technology supporting the development of tolerance immunotherapies designed to address the underlying drivers of inflammatory disease rather than managing symptoms alone. Barinthus Bio describes its approach as guiding the immune system to cure disease, a distinction it draws between its antigen-specific methodology and broader immunosuppressive strategies common in the I&I space. Headquartered in the United Kingdom, the company is listed and engages institutional investors through structured governance and regular news and filings activity. Its scientific founders come from leading research institutions, anchoring its discovery capabilities in a heritage of cutting-edge immunological innovation. Further information is available at vaccitech.co.uk.